Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
01:24pm, Tuesday, 25'th Aug 2020
Over a dozen regenerative medicine drugs have been launched, generating revenues approaching $4 billion in 2019.
Analysts Set Intellia Therapeutics Inc (NASDAQ:NTLA) PT at $21.75
08:48am, Saturday, 22'nd Aug 2020
Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have received a consensus recommendation of “Hold” from the nine analysts that are currently covering the company, Marketbeat reports. Five equiti
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
We're Not Worried About Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn
03:10pm, Tuesday, 11'th Aug 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although...
How Much Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Do Institutions Own?
03:06pm, Tuesday, 11'th Aug 2020
If you want to know who really controls Intellia Therapeutics, Inc. (NASDAQ:NTLA), then you'll have to look at the...
Credit Suisse Maintains a Hold Rating on Intellia Therapeutics (NTLA) - Markets
04:43pm, Friday, 07'th Aug 2020
In a report released yesterday, Martin Auster from Credit Suisse maintained a Hold rating on Intellia Therapeutics (NTLA – Research
Analysts Offer Insights on Healthcare Companies: Orthofix (NASDAQ: OFIX) and Intellia Therapeutics (NASDAQ: NTLA) - Markets
06:40pm, Thursday, 06'th Aug 2020
Analysts fell to the sidelines weighing in on Orthofix (OFIX – Research Report) and Intellia Therapeutics (NTLA – Research Report)
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
01:15pm, Thursday, 06'th Aug 2020
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 11.59% and 72.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the st
Intellia Therapeutics Announces Second Quarter 2020 Financial Results
11:30am, Thursday, 06'th Aug 2020
* Submitted first regulatory application to the U.K.’s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of transthyretin amyloidosis; on track to dose first patient by year-end * Ex
Global CRISPR Technology Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com
12:00am, Tuesday, 04'th Aug 2020
The
Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
12:00pm, Monday, 03'rd Aug 2020
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q2 Earnings Expected to Decline
04:33pm, Thursday, 30'th Jul 2020
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates
11:30am, Thursday, 30'th Jul 2020
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
